← Back to Clinical Trials
Recruiting NCT07261891
NCT07261891 Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT07261891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | prof. dr. Rik Schrijvers |
| Condition | Primary Immunodeficiency Diseases (PID) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2028-12-01 |
Trial Parameters
Condition Primary Immunodeficiency Diseases (PID)
Sponsor prof. dr. Rik Schrijvers
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-21
Completion 2028-12-01
Interventions
blood sampling
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy
Eligibility Criteria
Inclusion Criteria: * Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway. * Controls (B): participants eligible for inclusion in this study must fall in one of the following categories: * Healthy controls (without immune-mediated disease) Exclusion Criteria: * Children (\< 18 years at time of recruitment) * Persons unable or unwilling to give informed consent
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology